Don’t miss – Page 153 – Endpoints News

SIGN UP

AbbVie’s troubled $10B Rova-T cancer drug program takes a sudden turn toward the cliff

4 years ago

What do Martin Shkreli, Gilead and Takeda have in common? They all figure prominently in the new top-20 list of the world’s most expensive drugs

4 years ago

Bispecifics vs CAR-T: Analysts select the big winners — and losers — at #ASH18's biggest ever datapalooza

4 years ago

#ASH18: Can Amgen break through the BCMA CAR-T line and take a BiTE of the multiple myeloma market? It won't be quick or easy

4 years ago

#ASH18: Allogene ticks off a high CR rate for updated off-the-shelf CAR-T pioneer. But getting just the right kind of immunosuppression is crucial

4 years ago

#ASH18: Legend Biotech — allied with J&J now — continues to wow the crowd with their BCMA CAR-T update. What will bluebird say?

4 years ago

#ASH18: BeiGene works to bust through the checkpoint crowd with a pivotal readout that proves its PD-1 is better than the rest

4 years ago

#ASH18: Bluebird and Celgene didn’t 'break' their next-gen BCMA CAR-T, so now they’ll double down on the dose and root for real durability

4 years ago

#ASH18: Gilead posts impressive survival rates for Yescarta — but sales remain lean

4 years ago

#ASH18: Celgene offers up a stellar complete response rate for JCAR017. Will anyone notice?

4 years ago

#ASH18: Regeneron's bispecific REGN1979 offers eye-catching 80% CR rate in follicular lymphoma, spurring swift shift to pivotal study

4 years ago

#ASH18: Acceleron and Celgene take center stage with a pair of PhIIIs for luspatercept they believe will back up $2B-plus in revenue projections

4 years ago

Amarin just rolled out a battery of promising new data for Vascepa — brace yourself for the M&A chatter to come

4 years ago

Innovent, Eli Lilly cite a new success for their PD-1 in lung cancer, with a likely pioneering approval in China looming

4 years ago

Ex-Kerrisdale analyst sets out to torpedo Nektar with a blunt short attack on star drug NKTR-214: 'It doesn’t work'

4 years ago

GSK-backed scientific team at UCSF says they found the immortality switch in cancer cells — and know how to turn it off

4 years ago

David Schenkein is passing the reins at Agios to Jackie Fouse after a star-making 10-year run

4 years ago

Y-mAbs’ story comes into the light: a shipping tycoon, the MSK researcher, a partial hold and a $92M IPO gamble

4 years ago

The biotech mood at the halfway mark of 2018? Boisterous, focusing more attention on China and looking for accelerated progress

4 years ago

Biogen's high-stakes Alzheimer's gamble is being roasted by the experts. Is the amyloid beta theory dead?

4 years ago

Tom Hughes jumps ship at Zafgen and gets back to the helm of a noteworthy biotech

4 years ago

Game change: Pfizer doubles down on its late-stage pipeline as CEO Read disavows a long reliance on M&A deals

4 years ago

7 things you need to know now about raising biotech cash in China (Part 1)

4 years ago

The under-40s: How does the next generation of biopharma executives view the future?

5 years ago

First page Previous page 150 151 152153154 Next page Last page